209 related articles for article (PubMed ID: 4017947)
1. An evaluation of the role of antiestrogen-binding sites in mediating the growth modulatory effects of antiestrogens: studies using t-butylphenoxyethyl diethylamine, a compound lacking affinity for the estrogen receptor.
Sheen YY; Simpson DM; Katzenellenbogen BS
Endocrinology; 1985 Aug; 117(2):561-4. PubMed ID: 4017947
[TBL] [Abstract][Full Text] [Related]
2. Antiestrogen binding in antiestrogen growth-resistant estrogen-responsive clonal variants of MCF-7 human breast cancer cells.
Miller MA; Lippman ME; Katzenellenbogen BS
Cancer Res; 1984 Nov; 44(11):5038-45. PubMed ID: 6488162
[TBL] [Abstract][Full Text] [Related]
3. Resistance to tamoxifen with persisting sensitivity to estrogen: possible mediation by excessive antiestrogen binding site activity.
Pavlik EJ; Nelson K; Srinivasan S; Powell DE; Kenady DE; DePriest PD; Gallion HH; van Nagell JR
Cancer Res; 1992 Aug; 52(15):4106-12. PubMed ID: 1638522
[TBL] [Abstract][Full Text] [Related]
4. Antiestrogen action in breast cancer cells: modulation of proliferation and protein synthesis, and interaction with estrogen receptors and additional antiestrogen binding sites.
Katzenellenbogen BS; Miller MA; Mullick A; Sheen YY
Breast Cancer Res Treat; 1985; 5(3):231-43. PubMed ID: 4027393
[TBL] [Abstract][Full Text] [Related]
5. Antiestrogen pharmacology and mechanism of action.
Katzenellenbogen BS; Miller MA; Eckert RL; Sudo K
J Steroid Biochem; 1983 Jul; 19(1A):59-68. PubMed ID: 6887873
[TBL] [Abstract][Full Text] [Related]
6. Studies on the ligand specificity and potential identity of microsomal antiestrogen-binding sites.
Watts CK; Sutherland RL
Mol Pharmacol; 1987 May; 31(5):541-51. PubMed ID: 3553893
[TBL] [Abstract][Full Text] [Related]
7. Physicochemical and genetic evidence for specific antiestrogen binding sites.
Faye JC; Jozan S; Redeuilh G; Baulieu EE; Bayard F
Proc Natl Acad Sci U S A; 1983 Jun; 80(11):3158-62. PubMed ID: 6574477
[TBL] [Abstract][Full Text] [Related]
8. Estrogenic stimulation of the antiestrogen specific binding site in rat uterus and liver.
Winneker RC; Clark JH
Endocrinology; 1983 Jun; 112(6):1910-5. PubMed ID: 6682755
[TBL] [Abstract][Full Text] [Related]
9. Roles of antiestrogen binding sites in human endometrial cancer cells.
Hayashida M; Terakawa N; Shimizu I; Ikegami H; Wakimoto H; Aono T; Tanizawa O; Matsumoto K
J Steroid Biochem; 1987 Jun; 26(6):705-11. PubMed ID: 3613570
[TBL] [Abstract][Full Text] [Related]
10. Histamine and growth: interaction of antiestrogen binding site ligands with a novel histamine site that may be associated with calcium channels.
Brandes LJ; Bogdanovic RP; Cawker MD; LaBella FS
Cancer Res; 1987 Aug; 47(15):4025-31. PubMed ID: 2886214
[TBL] [Abstract][Full Text] [Related]
11. Tamoxifen inhibition of prolactin action in the mouse mammary gland.
Biswas R; Vonderhaar BK
Endocrinology; 1991 Jan; 128(1):532-8. PubMed ID: 1846110
[TBL] [Abstract][Full Text] [Related]
12. Antiestrogenic potency and binding characteristics of the triphenylethylene H1285 in MCF-7 human breast cancer cells.
Sheen YY; Ruh TS; Mangel WF; Katzenellenbogen BS
Cancer Res; 1985 Sep; 45(9):4192-9. PubMed ID: 4040807
[TBL] [Abstract][Full Text] [Related]
13. Antitumor activity of clomiphene analogs in vitro: relationship to affinity for the estrogen receptor and another high affinity antiestrogen-binding site.
Murphy LC; Sutherland RL
J Clin Endocrinol Metab; 1983 Aug; 57(2):373-9. PubMed ID: 6408114
[TBL] [Abstract][Full Text] [Related]
14. Antiestrogen inhibition of prolactin-induced growth of the Nb2 rat lymphoma cell line.
Biswas R; Vonderhaar BK
Cancer Res; 1989 Nov; 49(22):6295-9. PubMed ID: 2804977
[TBL] [Abstract][Full Text] [Related]
15. A new antiestrogen, 2-(4-hydroxy-phenyl)-3-methyl-1-[4-(2-piperidin-1-yl-ethoxy)-benzyl]-1H-indol-5-ol hydrochloride (ERA-923), inhibits the growth of tamoxifen-sensitive and -resistant tumors and is devoid of uterotropic effects in mice and rats.
Greenberger LM; Annable T; Collins KI; Komm BS; Lyttle CR; Miller CP; Satyaswaroop PG; Zhang Y; Frost P
Clin Cancer Res; 2001 Oct; 7(10):3166-77. PubMed ID: 11595711
[TBL] [Abstract][Full Text] [Related]
16. The pure antiestrogen ICI 182,780 binds to a high-affinity site distinct from the estrogen receptor.
Parisot JP; Hu XF; Sutherland RL; Wakeling A; Zalcberg JR; DeLuise M
Int J Cancer; 1995 Aug; 62(4):480-4. PubMed ID: 7635575
[TBL] [Abstract][Full Text] [Related]
17. Antiestrogenic activity of DP-TAT-59, an active metabolite of TAT-59 against human breast cancer.
Toko T; Shibata J; Nukatsuka M; Yamada Y
Cancer Chemother Pharmacol; 1997; 39(5):390-8. PubMed ID: 9054952
[TBL] [Abstract][Full Text] [Related]
18. Acceptor sites on chromatin for receptor bound by estrogen versus antiestrogen in antiestrogen-sensitive and -resistant MCF-7 cells.
Singh RK; Ruh MF; Butler WB; Ruh TS
Endocrinology; 1986 Mar; 118(3):1087-95. PubMed ID: 3948766
[TBL] [Abstract][Full Text] [Related]
19. Structure-activity relationships of nonisomerizable derivatives of tamoxifen: importance of hydroxyl group and side chain positioning for biological activity.
Murphy CS; Parker CJ; McCague R; Jordan VC
Mol Pharmacol; 1991 Mar; 39(3):421-8. PubMed ID: 2005879
[TBL] [Abstract][Full Text] [Related]
20. Differential effects of tamoxifen and analogs with nonbasic side chains on cell proliferation in vitro.
Murphy LC; Sutherland RL
Endocrinology; 1985 Mar; 116(3):1071-8. PubMed ID: 3971898
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
